{"filings":[{"id":121492,"accession_number":"0001193125-25-332152","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.03","8.01","9.01"],"status":"ready","headline":"Clearside Biomedical bankruptcy court approves sale process; Health Ocean Limited as stalking horse","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Court approved bidding procedures on Dec 19, 2025; Health Ocean Limited designated as stalking horse bidder.","Monthly operating report: $3.05M cash; net loss of $490,885 for seven days ending Nov 30, 2025.","Total assets negative $24.4M, equity negative $26.9M; prepetition unsecured debt $2.3M.","No employee payroll; no professional fees paid during period; court authorized tax payments.","Sale process subject to higher or better offers; auction to follow bidding procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121491,"accession_number":"0001193125-25-311305","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Clearside Biomedical files Form 25 to complete Nasdaq delisting after Chapter 11 bankruptcy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Form 25 on Dec 8, 2025 to delist from Nasdaq and deregister under Section 12(b); effective no earlier than Dec 18, 2025.","Nasdaq delisting notice received Nov 24, 2025 after Chapter 11 filing (Case No. 25-12109); trading suspended Dec 1, 2025.","Common stock trades on OTC Pink under symbol CLSDQ since Dec 1, 2025.","Deregistration will reduce SEC reporting obligations 90 days after Form 25 effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121490,"accession_number":"0001193125-25-297177","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["1.03","3.01","7.01","9.01"],"status":"ready","headline":"Clearside Biomedical files for Chapter 11 bankruptcy; Nasdaq delisting effective Dec 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed voluntary Chapter 11 petition on Nov 23, 2025 in Delaware (Case No. 25-12109).","Nasdaq delisting notice received; trading suspended Dec 1, moving to OTC under symbol CLSDQ.","Company intends to sell substantially all assets through a Section 363 auction.","First-day motions filed to continue normal operations during the bankruptcy process.","Assets include SCS Microinjector platform, CLS-AX program, and multiple licensing deals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121489,"accession_number":"0001193125-25-233470","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Clearside Biomedical regains Nasdaq minimum bid price compliance via reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq Panel letter on Oct 6, 2025 confirming compliance with Minimum Bid Price Requirement.","Compliance achieved by maintaining closing bid at $1.00+ for 10 consecutive business days after reverse stock split.","Reverse stock split effective Sept 12, 2025 was approved by stockholders and implemented to cure non-compliance.","Non-compliance notice originally received Feb 7, 2025; delisting hearing held Sept 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138168,"accession_number":"0001193125-25-200747","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Clearside Biomedical files 1-for-15 reverse stock split, reduces authorized shares to 26.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective September 12, 2025 at 5:00 p.m. ET; split-adjusted trading begins September 15, 2025.","Every 15 outstanding shares combine into 1; no fractional shares issued – cash in lieu.","Authorized common stock reduced from 400M to 26,666,666; par value unchanged at $0.001.","Proportionate adjustments to stock options, RSUs, warrants, and equity plan reserves.","New CUSIP 185063203; Nasdaq ticker CLSD unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138167,"accession_number":"0000950170-25-114089","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Clearside Biomedical announces 1-for-15 reverse stock split, authorized shares reduced to 26.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-15 ratio; effective 5:00 p.m. ET on Sept 12, 2025.","Authorized shares reduced from 400M to 26,666,666; no change to par value.","Trading on split-adjusted basis on Nasdaq Capital Market starting Sept 15, 2025; new CUSIP 185063203.","No fractional shares; cash paid in lieu; proportionate adjustments to stock options, RSUs, warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138166,"accession_number":"0000950170-25-113362","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Clearside Biomedical receives additional $3M from Healthcare Royalty; reduces royalty cap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered Omnibus Amendment with Healthcare Royalty Partners; received $3.0M for remaining SCS Microinjector assets.","Royalty threshold for expiration reduced from $110.5M to $106.5M; potential lower future payments.","Purchaser waived right to foreclose on Seller capital stock in specified circumstances.","All other terms of original 2022 Purchase/Sale and Contribution Agreements remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138165,"accession_number":"0001193125-25-194994","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["3.01","5.07"],"status":"ready","headline":"Clearside Biomedical gets Nasdaq MVLS deficiency notice; stockholders approve reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Aug 28, 2025 for non-compliance with $50M MVLS requirement for continued listing on Global Market.","Company has 180 days until Feb 24, 2026 to regain compliance; may consider transfer to Nasdaq Capital Market.","At special meeting Aug 29, 2025, stockholders approved reverse stock split in range of 1-for-5 to 1-for-15 to address bid price deficiency.","Reverse stock split approved with 46.5M for, 2.2M against, 459k abstained out of 49.2M shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138164,"accession_number":"0000950170-25-108846","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Clearside receives Nasdaq delisting notice; Chairperson Gibney resigns, Thorp succeeds","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Clearside on Aug 11, 2025 that its common stock is subject to delisting due to bid price below $1.00 for 30 consecutive business days.","Clearside intends to request a hearing before Nasdaq Panel to stay delisting; stock will continue trading pending hearing process.","Company is seeking stockholder approval for a reverse stock split at ratio 1-for-5 to 1-for-15 to regain minimum bid price compliance.","Anthony Gibney resigned as Chairperson and board member effective Aug 11, 2025; appointed CFO of Aura Biosciences; no dispute.","Board appointed existing member Clay B. Thorp as new Chairperson effective Aug 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138163,"accession_number":"0000950170-25-096438","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["2.05","5.02","8.01","9.01"],"status":"ready","headline":"Clearside explores strategic alternatives; all employees terminated, R&D paused","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All employees, including CEO, CFO, CMO, terminated effective July 18, 2025, transition to consulting roles.","Estimated $3.4M severance charges in Q3 2025; internal R&D programs paused.","Retained Piper Sandler to evaluate sale, license, merger, or other strategic transactions.","No agreement reached; no timetable set; no assurance any transaction will occur.","CLS-AX Phase 3-ready in wet AMD; SCS Microinjector platform with five licensing partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155598,"accession_number":"0000950170-25-079689","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Clearside Biomedical shareholders approve doubling authorized common stock to 400M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common shares from 200M to 400M; 38.8M for, 10.3M against, 0.6M abstain.","All three director nominees (Lasezkay, Shaffer, Gibney) were elected with >25M votes for.","Advisory vote on executive compensation approved: 18.9M for, 3.4M against, 6.8M abstain.","Ratification of Ernst & Young as auditor for FY2025 approved: 48.5M for, 1.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155597,"accession_number":"0000950170-25-071386","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Biomedical Q1 net loss narrows to $8.2M; FDA agrees on Phase 3 plan for CLS-AX in wet AMD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.2M ($0.11/sh) vs $11.8M ($0.17) YoY; license revenue $2.3M (up from $0.2M) on Arctic Vision milestone.","Successful End-of-Phase 2 FDA meeting; alignment on Phase 3 design for CLS-AX targeting 3-6 month flexible dosing in wet AMD.","Partner Arctic Vision: ARCATUS approved in Australia and Singapore; NDA accepted for review in China for uveitic macular edema.","Partner BioCryst authorized to start clinical trial for avoralstat in DME using Clearside's SCS Microinjector; initial data expected in 2025.","Cash $13.6M at March 31, expected to fund operations into Q4 2025."],"consensus_eps_estimate":-1.6611,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":2330000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174091,"accession_number":"0000950170-25-046085","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Clearside posts Q4 net loss $7.3M; cash to Q4 2025; FDA aligns on CLS-AX Phase 3 in wet AMD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $7.3M ($0.10/sh) vs $4.8M ($0.08) in Q4 2023; FY loss $34.4M ($0.47) vs $32.5M ($0.53).","Cash $20.0M at Dec 31, 2024; expected to fund operations into Q4 2025.","FDA alignment on Phase 3 for CLS-AX in wet AMD: two non-inferiority trials, sham control, after positive Phase 2b.","Partner Arctic Vision NDA for ARCATUS (XIPERE) in uveitic macular edema accepted in China; also approved in Australia and Singapore.","Tony Gibney appointed Chair of Board effective November 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174090,"accession_number":"0000950170-25-019866","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Clearside Biomedical receives Nasdaq minimum bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Feb 7, 2025; stock below $1.00 for 30 consecutive business days.","Company has 180 days (until Aug 6, 2025) to regain compliance.","To cure, bid price must close at $1.00+ for 10 consecutive business days.","Options include transfer to Nasdaq Capital Market or reverse stock split.","Failure to comply may result in delisting; company intends to monitor and seek remedies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191048,"accession_number":"0000950170-24-135823","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Clearside updates corporate presentation; specifics in slides 31-37 not visible in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing furnishes updated investor deck for analyst and investor meetings.","Slides 31 through 37 incorporated by reference under Item 8.01.","Exhibit 99.1 only shows title page; material details cannot be extracted from provided text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191047,"accession_number":"0000950170-24-125385","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Q3 2024 net loss $7.7M; ODYSSEY Phase 2b wet AMD trial hits all endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.7M ($0.10 per share) vs. $9.3M ($0.15) in Q3 2023; revenue $1.0M, up from $0.9M.","ODYSSEY Phase 2b of suprachoroidal CLS-AX in wet AMD met all primary and secondary outcomes with extended duration.","Cash, equivalents and short-term investments $23.6M as of Sep 30, 2024; runway into Q3 2025.","Asia-Pacific partner Arctic Vision licensed ARVN001 to Santen for China; Phase 3 UME data positive.","Tony Gibney appointed Chair of Board; REGENXBIO advances ABBV-RGX-314 via SCS Microinjector toward pivotal trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":1358000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191046,"accession_number":"0000950170-24-113631","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Clearside reports positive ODYSSEY Phase 2b results for CLS-AX in wet AMD; all endpoints met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ODYSSEY Phase 2b trial of suprachoroidal CLS-AX achieved primary and secondary outcomes; stable BCVA and CSRT through 36 weeks.","67% of CLS-AX participants required no additional treatment up to 6 months; 90% up to 4 months, 81% up to 5 months.","Treatment burden reduced by ~84% compared to average monthly injections prior to screening.","No ocular or treatment-related SAEs; no endophthalmitis, no retinal vasculitis; well-tolerated safety profile.","Company plans to advance CLS-AX into Phase 3 development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207520,"accession_number":"0000950170-24-095451","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Biomedical Q2 net loss narrows to $7.6M; Phase 2b wet AMD trial on track for late Q3 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.6M ($0.10/sh) vs $9.1M ($0.15/sh) in Q2 2023; license revenue $90,000.","Phase 2b ODYSSEY topline data for wet AMD expected late Q3 2024; no drug-related SAEs observed.","Cash and investments total $29.4M; company expects operations funded into Q3 2025.","Arctic Vision reports positive Phase 3 ARCATUS results; NDAs accepted in Australia and Singapore.","Tony Gibney appointed to Board; Dr. Glenn Yiu added to Scientific Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":320000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207519,"accession_number":"0000950170-24-085864","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Clearside Biomedical holds KOL webinar on suprachoroidal delivery; no new financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company hosted virtual Suprachoroidal Delivery KOL Webinar on July 24, 2024.","Attached slide presentation (Exhibit 99.1) contains only a title slide with no substantive data.","No material financial or business updates were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224943,"accession_number":"0000950170-24-075603","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Clearside Biomedical stockholders elect all three director nominees, approve say-on-pay, ratify E&Y","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Croarkin, Humphries, and Hutson elected with ~30M votes for each; no nominee withheld.","Advisory vote on executive compensation approved: 22.8M for, 5.2M against, 6.6M abstentions.","Ratification of Ernst & Young as independent auditor for FY2024 passed: 45.1M for, 4.9M against.","Total shares present at meeting: 50.1M (67% of 74.7M outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224942,"accession_number":"0000950170-24-056958","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside reports Q1 net loss $11.8M, $0.17/sh; cash $35.4M; ODYSSEY topline due Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.8M ($0.17/sh) vs $9.3M ($0.15) Q1 2023; revenue $230K up from $4K.","Cash $35.4M expected to fund operations into Q3 2025.","Phase 2b ODYSSEY trial of CLS-AX in wet AMD topline data expected Q3 2024.","Appointed Victor Chong as CMO (March 2024) and Tony Gibney to Board (April 2024).","Completed $15M registered direct offering in Feb 2024; new CPT code for XIPERE effective Jan 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":230000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224941,"accession_number":"0000950170-24-044594","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Clearside Biomedical appoints Anthony S. Gibney to its Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mr. Gibney appointed as a Class III director effective April 15, 2024; term runs through 2025 annual meeting.","He brings over 25 years biotech experience including Iveric Bio, Achillion, and Leerink Partners.","Received an option to purchase 45,000 shares of CLSD common stock vesting over 36 months.","Entitled to $40,000 annual retainer plus additional annual option grants for continuous service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244201,"accession_number":"0000950170-24-029956","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Biomedical Q4 2023 net loss narrows to $4.8M; cash runway to Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 of $4.8M ($0.08/shr) improved from $9.7M loss ($0.16/shr) in Q4 2022.","License revenue Q4 2023 of $6.3M, up from $0.3M, driven by $5M BioCryst upfront and $1M Aura milestone.","Cash $28.9M at Dec 31; subsequent $15M equity offering extends runway into Q3 2025.","Phase 2b ODYSSEY wet AMD trial topline data expected Q3 2024; randomization completed Dec 2023.","Full year 2023 net loss $32.5M ($0.53/shr) vs $32.9M ($0.55/shr) in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244200,"accession_number":"0001193125-24-028487","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Clearside Biomedical prices $15M registered direct offering of 11.1M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$15M from sale of 11,111,111 shares and warrants at $1.35 per unit.","Warrants exercisable at $1.62/share for 5 years from August 2024.","Offering expected to close February 9, 2024 with Citizens JMP Securities as placement agent.","Net proceeds for working capital; management says cash runway extends into Q3 2025.","Placement agent fee of 6.0% of gross proceeds plus reimbursement of expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244199,"accession_number":"0000950170-24-009767","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Clearside reduces sublicense fees to high single digit; maintenance fees set $250K-$500K for 2023-2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublicense percentage reduced from low double digits to high single digits for fees received from sublicensees.","Maintenance fees: $250K for 2023-2025, $350K for 2026, $400K for 2027, $500K for 2028.","2023 maintenance fee of $250K due within 5 days of amendment execution (Jan 31, 2024).","Reduced sublicense fee excludes R&D reimbursements, IP value transfers, and stock payments.","Royalty rate on product sales remains unchanged at low single digit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261619,"accession_number":"0000950170-23-073587","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Clearside Biomedical waives $12.5M milestone payment, releases escrow to HCR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subsidiary Clearside Royalty waived all rights to $12.5M milestone payment tied to XIPERE sales.","Payment held in escrow under 2022 Purchase Agreement; released to Healthcare Royalty Partners IV.","First Milestone Event required milestone by March 31, 2024; waiver eliminates potential payment.","Escrow agreement terminated upon release of funds to purchaser."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261618,"accession_number":"0000950170-23-062941","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Q3 net loss $9.3M; inks BioCryst licensing deal for DME with $5M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.3M ($0.15/share) vs $7.8M loss ($0.13/share) in Q3 2022.","Cash $28.8M at Sep 30; +$5M upfront from BioCryst extends runway into Q4 2024.","Licensed avoralstat (plasma kallikrein inhibitor) to BioCryst for DME; up to $77.5M milestones plus royalties.","Completed recruitment in Phase 2b ODYSSEY wet AMD trial; topline data expected Q3 2024.","Arctic Vision finished Phase 3 UME trial enrollment in China; Bausch+Lomb granted new CPT code for XIPERE."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1881000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261617,"accession_number":"0000950170-23-058627","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Clearside Biomedical licenses SCS Microinjector to BioCryst for avoralstat in DME","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clearside granted BioCryst exclusive worldwide license to use SCS Microinjector for avoralstat in diabetic macular edema.","Upfront fee of $5.0 million; eligible for up to $30.0 million in clinical/regulatory milestones and $47.5 million in sales-based milestones.","Tiered mid-single digit royalties on annual global net sales, highest rate on sales over $1.5 billion.","BioCryst responsible for all development, regulatory, and commercialization; Clearside to supply SCS Microinjectors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278840,"accession_number":"0000950170-23-050819","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Clearside Biomedical receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sept 27, 2023 for non-compliance with minimum bid price rule.","Must regain compliance by March 25, 2024; bid price must close at $1.00+ for 10 consecutive days.","May transfer to Nasdaq Capital Market or effect a reverse stock split to cure the deficiency.","Failure to regain compliance could lead to delisting, impairing liquidity and capital access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278839,"accession_number":"0000950170-23-042410","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Q2 net loss $9.1M; Phase 2b ODYSSEY enrollment underway, topline Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.1M ($0.15/share) vs $7.8M ($0.13) prior year; cash $35.0M, operations funded into Q3 2024.","Phase 2b ODYSSEY trial for CLS-AX in wet AMD actively enrolling at ~30 U.S. sites; topline data expected Q3 2024.","Partner Arctic Vision's NDA accepted in Australia for Arcatus (suprachoroidal treatment of uveitic macular edema).","R&D expenses $4.9M (down from $5.4M); license revenue $1.0M (up from $0.4M).","Board Chair changed to Clay B. Thorp; Scientific Advisory Board expanded with three new members."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":1022000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297099,"accession_number":"0000950170-23-029413","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Clearside Biomedical shareholders re-elect all three director nominees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeffrey L. Edwards, Clay B. Thorp, and Benjamin R. Yerxa re-elected with 21.0M, 21.0M, and 22.8M votes for, respectively.","Advisory vote on executive compensation passed with 21.9M for, 1.0M against, 2.3M abstain.","Ratification of Ernst & Young as auditor for FY 2023 approved (40.2M for, 0.1M against).","Turnout: 40.7M shares (65.98%) of 61.7M outstanding present or represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297098,"accession_number":"0000950170-23-021769","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Clearside terminates Cowen ATM facility, enters new up to $50M at-the-market equity deal with Cantor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated prior Cowen Sales Agreement effective May 12, 2023; $35.8M net raised from ~19M shares since 2017.","Entered new Controlled Equity Offering with Cantor Fitzgerald to sell up to $50M of common stock at-the-market.","Cantor will receive up to 3% commission on gross sales; Company not obligated to sell any shares.","New facility provides ongoing equity capital access for the biotech firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297097,"accession_number":"0000950170-23-020831","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Biomedical Q1 net loss $9.3M; Phase 2b ODYSSEY trial to open Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.3M ($0.15 per share) vs $7.6M ($0.13) in Q1 2022.","Cash and equivalents $41.4M; company expects to fund operations into Q2 2024.","R&D expenses flat at $4.5M; G&A down to $3.2M from $3.5M.","Phase 2b ODYSSEY trial of CLS-AX in wet AMD to open enrollment Q2 2023; topline results expected Q3 2024.","Positive safety and duration data from OASIS Phase 1/2a extension study presented at ARVO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":4000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297096,"accession_number":"0000950170-23-013165","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Clearside Biomedical announces plans for Phase 2b ODYSSEY trial of CLS-AX in wet AMD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b trial ODYSSEY to enroll 60 patients with wet AMD; 2:1 randomization CLS-AX vs aflibercept.","Primary outcome: mean change in BCVA from baseline to Week 36; secondary include CST and treatment burden.","CLS-AX arm: 3 aflibercept loading doses + CLS-AX at baseline, then at least every 24 weeks.","Enrollment starts Q2 2023; topline results expected in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317469,"accession_number":"0000950170-23-007037","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Biomedical reports Q4 net loss of $9.7M; Phase 2b wet AMD trial on track for Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $9.7M ($0.16/share) vs net income $18.7M ($0.31/share) in Q4 2021 on lower license revenue.","Full-year 2022 net loss $32.9M ($0.55/share) vs net income $376K ($0.01/share) in 2021.","Cash $48.3M at Dec 31, 2022; runway into Q2 2024.","Phase 2b ODYSSEY trial of CLS-AX in wet AMD to start Q2 2023; comparator arm adjusted to on-label aflibercept per FDA draft guidance.","Bausch + Lomb trained over 1,000 retinal physicians on SCS Microinjector for XIPERE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317468,"accession_number":"0000950170-23-003293","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Clearside Biomedical CMO Thomas Ciulla resigns, becomes advisor under consulting agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Ciulla resigned as CMO and CDO effective Feb 17, 2023; will serve as Chairman of Scientific Advisory Board and Chief Medical Advisor – Retina.","Consulting fee of $8,000 per month; initial term one year, renewable at Company's option.","Stock options continue vesting through Aug 31, 2023 (Jan 4, 2023 option through Jan 4, 2024); RSU vesting ceased on Feb 17, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317467,"accession_number":"0000950170-23-001831","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Clearside Biomedical CMO/CVO Thomas Ciulla resigns effective Feb 17; will serve as advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Ciulla resigns as Chief Medical Officer and Chief Development Officer of Clearside Biomedical.","Resignation effective February 17, 2023; he will continue as Chairman of Scientific Advisory Board.","Ciulla will also serve as Chief Medical Advisor – Retina under a proposed consulting agreement.","No successor named; Ciulla’s advisory role aims to maintain continuity in clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317466,"accession_number":"0001193125-23-022182","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Positive OASIS extension results: 67% of wet AMD patients went ≥6 months without retreatment; cash $48.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["67% of extension participants (8/12) went ≥6 months without additional treatment; 50% went >6 months.","Treatment burden reduced 77-85% vs. average monthly injections prior to CLS-AX administration.","No serious adverse events, inflammation, vasculitis, or vascular occlusion; excellent safety profile.","Planned initiation of Phase 2b ODYSSEY trial in Q1 2023 with primary endpoint readout mid-2024.","Preliminary unaudited cash and cash equivalents of $48.3M as of December 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335711,"accession_number":"0000950170-22-023528","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Clearside reports Q3 net loss of $7.8M; OASIS trial shows positive durability for CLS-AX","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 2022 net loss of $7.8M ($0.13/share) vs $4.9M loss in Q3 2021; revenue fell to $0.3M from $3.1M.","OASIS Phase 1/2a met primary safety endpoint; no serious adverse events in 27 wet AMD patients.","Cohorts 3/4: 88% injection-free to Month 5, 75% to Month 6; >90% reduction in treatment burden.","Company expects to initiate Phase 2 trial for CLS-AX in wet AMD in Q1 2023.","Entered royalty interest sale with HealthCare Royalty for up to $65M non-dilutive funding; cash $53.4M, runway into 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353150,"accession_number":"0000950170-22-015746","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside reports Q2 loss of $7.8M, secures $65M non-dilutive financing, OASIS data due Nov","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.8M ($0.13/shr) vs $6.1M ($0.11/shr) in Q2 2021; license revenue $384K down from $780K.","Cash $29.0M at June 30; initial $32.5M royalty payment from HealthCare Royalty extends runway into 2024.","CLS-AX OASIS Phase 1/2a top-line data for all four cohorts expected November 2022.","Non-dilutive financing up to $65M: $32.5M initial, $12.5M escrow, $20M milestone upon XIPERE sales targets.","Appointed Susan L. Coultas, Ph.D., as Chief Clinical Officer; XIPERE J-code effective July 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":731000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353149,"accession_number":"0000950170-22-015582","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Clearside Biomedical enters royalty financing with HealthCare Royalty for up to $65M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront cash of $32.5M; additional $12.5M escrow tied to XIPERE sales milestone, plus up to $20M second milestone.","HealthCare Royalty receives royalties from XIPERE and SCS Microinjector license deals until 2.5x (or 3.4x) payback achieved.","Proceeds intended to support CLS-AX (axitinib injectable suspension) clinical program via suprachoroidal injection.","Deal excludes Clearside's internal pipeline and future in-licensed assets; non-dilutive capital.","Transaction expected to close in August 2022; JMP Securities acted as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370800,"accession_number":"0000950170-22-012039","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2022-06-23T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Clearside Biomedical shareholders approve doubling authorized common stock to 200M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common shares from 100M to 200M (32.6M for, 4.4M against, 6.0M abstain).","Directors George Lasezkay and Christy Shaffer elected with 25.9M and 24.8M votes for, respectively.","Advisory vote on executive compensation passed with 27.6M for, 3.0M against; annual frequency chosen.","Ratification of Ernst & Young as auditor for FY2022 received 42.9M votes for, 88.8K against.","Annual meeting turnout: 43.0M of 60.2M shares represented (71.55% quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370799,"accession_number":"0000950170-22-009366","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Biomedical Q1 2022 net loss $7.6M; CLS-AX cohort 4 enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.6M ($0.13 per share) vs $7.4M ($0.13) in Q1 2021; revenue $347K vs $34K.","Cash and equivalents $34.4M; company expects sufficient for at least next 12 months.","XIPERE (suprachoroidal triamcinolone) commercially launched in U.S. by Bausch + Lomb for uveitic macular edema.","CLS-AX Phase 1/2a OASIS trial: Cohort 4 enrolling at 1.0 mg; no dose-limiting toxicities in Cohort 3; safety data expected Q4 2022.","Benjamin R. Yerxa appointed to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":347000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389841,"accession_number":"0000950170-22-003368","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Biomedical Q4 2021 net income $18.7M on XIPERE milestones; CLS-AX trial advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 license revenue $25.7M (vs $11K in Q4 2020) from $20M in XIPERE milestones; net income $18.7M ($0.31/sh) vs net loss $7.1M.","Full year 2021 revenue $29.6M (vs $7.9M in 2020); net income $376K ($0.01/sh) vs net loss $18.2M in 2020.","Cash $30.4M at Dec 31, 2021 plus $10M collected in Q1 2022; expects to fund operations into Q2 2023.","CLS-AX OASIS Phase 1/2a: Cohort 3 results expected mid-2022; new Cohort 4 planned Q2 2022 to explore higher doses.","XIPERE launched by Bausch + Lomb in U.S. in Q1 2022 for uveitic macular edema after FDA approval Oct 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389840,"accession_number":"0000950170-22-002728","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Clearside Biomedical appoints Benjamin Yerxa, Ph.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Yerxa, CEO of Foundation Fighting Blindness and Clearside co-founder, appointed effective March 2, 2022.","Received option to purchase 30,000 shares at $1.49/share, vesting in 36 monthly installments.","Entitled to $40,000 annual retainer plus annual option grants for service as director.","His expertise expected to advance CLS-AX (axitinib) for wet AMD and SCS platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407813,"accession_number":"0000950170-21-005294","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Clearside reports positive safety results from OASIS Phase 1/2a trial of CLS-AX for wet AMD; dose escalation to 0.5 mg","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort 2 (0.1 mg CLS-AX, n=5) well-tolerated: no serious adverse events, no treatment-related AEs, no vitreous dispersion.","Combined Cohorts 1 & 2 (n=11): 36% of patients had no retreatments for ≥3 months; 55% for ≥2 months.","Mean best corrected visual acuity (BCVA) and central subfield thickness (CST) were stable in the first two cohorts.","Safety Monitoring Committee approved escalation to Cohort 3 (0.5 mg CLS-AX); patient screening has begun."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407812,"accession_number":"0000950170-21-004087","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside Biomedical reports Q3 loss of $0.08/share; XIPERE approval triggers $19M milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XIPERE (triamcinolone acetonide) approved by FDA in Oct 2021 for macular edema associated with uveitis; first product for suprachoroidal injection.","Approval and pre-launch milestones from partners expected to provide $19M non-dilutive funding, extending cash runway into 2023.","Q3 2021 net loss $4.9M ($0.08 per share) vs $2.4M ($0.05 per share) in Q3 2020; revenue $3.1M vs $3.4M.","Cash and cash equivalents $25.2M as of Sep 30, 2021.","Phase 1/2a OASIS trial of CLS-AX (axitinib) in wet AMD completed dosing in Cohort 2; safety data expected by end of 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":3888000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407811,"accession_number":"0000950170-21-002256","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2021-10-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves Clearside's XIPERE for macular edema associated with uveitis; first suprachoroidal therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["XIPERE (triamcinolone acetonide injectable suspension) is the first FDA-approved therapy for suprachoroidal injection.","Phase 3 PEACHTREE trial: 47% of XIPERE patients achieved ≥15-letter BCVA improvement vs 16% sham (p<0.01) at Week 24.","Bausch + Lomb markets XIPERE; expected availability Q1 2022 under Clearside's SCS Microinjector delivery system.","This is Clearside's first commercial product and the first approved treatment specifically for macular edema associated with uveitis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426838,"accession_number":"0000950170-21-001181","cik":1539029,"company_name":"Clearside Biomedical, Inc.","ticker":"CLSDQ","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Clearside reports Q2 2021 net loss $6.1M; OASIS Cohort 2 underway; XIPERE PDUFA Oct 30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.1M ($0.11/share) vs $5.8M ($0.13/share) in Q2 2020.","Revenue of $0.8M from partner licensing; cash $26.4M to fund ops into Q2 2022.","OASIS Phase 1/2a wet AMD: Cohort 1 met safety endpoints; Cohort 2 enrollment (0.1 mg dose) underway.","XIPERE NDA resubmission accepted; FDA PDUFA action date of October 30, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":814000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1620000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}